This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In a majority of patients CML is diagnosed when they are in the chronic phase (CP) which is asymptomatic for prolonged periods (1).

Symptoms appear when there is expansion of CML cells (2). The clinical features of CML may be classified into:

  • non-specific systemic features:
    • anaemia
    • malaise & fatigue
    • weight loss
    • sweating
  • common features:
    • bleeding diathesis:
      • discrete ecchymoses
      • menorrhagia
    • splenomegaly
  • hepatomegaly
  • rare features:
    • abdominal pain or pleuritic pain due to splenic infarction
    • gout
    • signs and symptoms of hyperviscosity due to leukocytosis - retinal haemorrhages, priapism, cerebrovascular accidents, tinnitus (2)
    • fever

Signs and symptoms which indicate a progressive disease (from chronic phase through accelerated phase to blastic phase) include:

  • progressive leukocytosis
  • thrombocytosis or thrombocytopenia
  • anemia
  • increasing and painful splenomegaly or hepatomegaly
  • fever
  • bone pain
  • development of destructive bone lesions.
  • thrombotic or bleeding complications (3).

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.